Due to populations around the world getting older and chronic disease burden increasing, demand for healthcare services continues to rise.
I believe this trend will continue for several decades, which could make the healthcare sector a great place to look for investments.
Two ASX healthcare shares that I feel could be long-term market beaters are listed below. Here’s why I like them:
CSL Limited (ASX: CSL)
The first ASX healthcare share to consider buying is CSL. It is one of the world’s leading biotherapeutics companies. I feel it would be a great long term option for investors due to the quality of its CSL Behring and Seqirus businesses. CSL Behring is the global leader in plasma therapies and Seqirus is the second largest influenza vaccines business.
I believe both businesses are well-placed for long-term growth due to their leading therapies and their lucrative research and development pipelines. This pipeline contains a number of highly promising products that have the potential to generate significant revenues in the future. This includes clazakizumab, which is being developed to treat kidney transplant rejection. This product alone could generate peak sales of US$5.4 billion eventually.
ResMed Inc. (ASX: RMD)
A final healthcare share to consider buying is ResMed. It has been growing at a very strong rate over the last decade and is now one of the world’s leading sleep treatment companies. Pleasingly, it has started the new decade just as strongly as it finished the last. It was a strong performer in FY 2020, delivering a 15% constant currency increase in revenue to US$2,957 million and a 32% jump in net income to US$692.8 million.
The good news is that I believe it is well-placed to continue this strong form for some time to come. This is thanks to its world-class products and the massive number of undiagnosed sleep apnoea sufferers globally. The company also has a rapidly growth digital health ecosystem, which reached over 12 million cloud connectable medical devices this year. This provides ResMed with strong recurring revenues and an invaluable amount of high quality data.
These stocks could rocket in a Post-COVID world (FREE STOCK REPORT)
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
Find out the names of our 3 Post COVID Stocks – For FREE!
*Returns as of 6/8/2020
More reading
- Why a recession shouldn’t matter for the ASX share market
- Where to invest $5,000 into ASX shares right now
- 3 ASX 200 shares to buy for strong returns
- UBS picks the best and worst ASX stocks from the reporting season
- A strange thing is happening with index funds…
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post 2 of the best ASX healthcare shares to buy today appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/3lURbH4
Leave a Reply